Impact of LAG-3/FGL1 pathway on immune evasive contexture and clinical outcomes in advanced urothelial carcinoma

被引:1
|
作者
Yoshida, Takashi [1 ,2 ,3 ,4 ]
Nakamoto, Takahiro [1 ,5 ]
Atsumi, Naho [4 ,5 ]
Ohe, Chisato [1 ,6 ]
Sano, Takeshi [1 ]
Yasukochi, Yoshiki [7 ]
Tsuta, Koji [4 ,5 ]
Kinoshita, Hidefumi [1 ]
机构
[1] Kansai Med Univ, Dept Urol & Androl, Osaka, Japan
[2] Tottori Univ, Grad Sch Engn, Tottori, Japan
[3] Osaka Saiseikai Noe Hosp, Dept Urol, Osaka, Japan
[4] Kansai Med Univ, Corp Sponsored Res Programs Multicellular Interact, Osaka, Japan
[5] Kansai Med Univ, Dept Pathol, Osaka, Japan
[6] Osaka Metropolitan Univ, Grad Sch Med, Dept Pathol, Osaka, Japan
[7] Kansai Med Univ, Inst Biomed Sci, Dept Genome Anal, Osaka, Japan
基金
日本学术振兴会;
关键词
Immunotherapy; Solid tumor; Immune Checkpoint Inhibitor; co-inhibitory molecule; T-CELLS; EXPRESSION; TIM-3; NIVOLUMAB; RESPONSES; THERAPY; TIGIT;
D O I
10.1136/jitc-2024-009358
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Anti-programmed death-1 (PD-1)/anti-PD-ligand-1 (PD-L1) pathway inhibition is a standard regimen for advanced urothelial carcinoma (UC); however, its limited efficacy has been reflected in reported medium response rates. This study explored the role of next-generation coinhibitory receptors (IRs; lymphocyte activation gene 3 (LAG-3), T-cell immunoglobulin and mucin domain 3 (TIM-3), and T-cell immunoreceptor with Ig and ITIM domains (TIGIT)) and their ligands (LGs) in the response to PD-(L)1 blockade therapy and the oncological outcomes in patients with UC.Methods We investigated metastatic UC cases who underwent PD-(L)1 therapy (cohort 1: n=348, cohort 2: n=89, and cohort 4: n=29) or advanced UC cases involving surgery (cohort 3: n=293 and cohort 5: n=90). We assessed the mRNA expression profiles and corresponding clinical information regarding IRs and LGs using cohorts 1, 2, and 3. Additionally, we elucidated the spatial features of these targeted markers using multiplex immunohistochemistry (mIHC) on formalin-fixed paraffin-embedded samples from cohorts 4 and 5. Survival, differential expressed gene, and Gene Set Enrichment analyses were performed. For mIHC, quantitative analyses were also performed to correlate immune and tumor cell densities with patient survival.Results LAG-3 expression was strongly associated with the responsiveness of PD-(L)1 blockade compared with the expression of TIM-3 and TIGIT. In tumors with high LAG-3 levels, the increased expression of fibrinogen-like protein 1 (FGL1) had a significantly negative effect on the response to PD-(L)1 blockade and overall survival. Moreover, high FGL1 levels were associated with elevated CD4+ regulatory T-cell gene signatures and the upregulation of CD39 and neuropilin-1, with both indicating CD8+ T-cell exhaustion. mIHC analyses revealed that patients with stromal CD8+LAG-3+cellshigh-tumor FGL1+cellshigh exhibited a significant negative correlation with survival rates compared with those with stromal CD8+LAG-3+cellshigh-tumor FGL1+cellslow.Conclusions LAG-3 expression and high FGL1 coexpression are important predictive factors of adverse oncological outcomes related to the presence of immunosuppressive contextures. These findings are hypothesis-generating, warranting further mechanistic and clinical studies aimed to evaluate LAG-3/FGL1 blockade in UC.
引用
收藏
页码:1 / 14
页数:14
相关论文
共 28 条
  • [1] Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer
    Shi, An-Ping
    Tang, Xi-Yang
    Xiong, Yan-Lu
    Zheng, Kai-Fu
    Liu, Yu-Jian
    Shi, Xian-Gui
    Lv, Yao
    Jiang, Tao
    Ma, Nan
    Zhao, Jin-Bo
    FRONTIERS IN IMMUNOLOGY, 2022, 12
  • [2] Development of LAG-3/FGL1 blocking peptide and combination with radiotherapy for cancer immunotherapy
    Qian, Yuzhen
    Sun, Yixuan
    Shi, Peishang
    Zhou, Xiuman
    Zhang, Qiongqiong
    Dong, Qingyu
    Jin, Shengzhe
    Qiu, Lu
    Niu, Xiaoshuang
    Zhou, Xiaowen
    Zhao, Wenshan
    Wu, Yahong
    Zhai, Wenjie
    Gao, Yanfeng
    ACTA PHARMACEUTICA SINICA B, 2024, 14 (03) : 1150 - 1165
  • [3] Development of a high-throughput TR-FRET screening assay for LAG-3/FGL1 interaction
    Abdel-Rahman, Somaya A.
    Zhang, Longfei
    Gabr, Moustafa T.
    SLAS DISCOVERY, 2023, 28 (04) : 188 - 192
  • [4] Spatial Mapping and Clinical Significance of the LAG-3/FGL1 Pathway in Non-small Cell Lung Cancer Using High-Dimensional Tissue Imaging
    Desai, S. S.
    Sanmamed, M. F.
    Wang, J.
    Schalper, K. A.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S25 - S25
  • [5] Unlocking therapeutic potential: Targeting lymphocyte activation Gene-3 (LAG-3) with fibrinogen-like protein 1 (FGL1) in systemic lupus erythematosus
    Wang, Bing
    Zhang, Biqing
    Wu, Min
    Xu, Ting
    JOURNAL OF TRANSLATIONAL AUTOIMMUNITY, 2024, 9
  • [6] Tumor LAG-3 and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer
    Jung, Eun Hee
    Jang, Hee Ryeong
    Kim, Se Hyun
    Suh, Koung Jin
    Kim, Yu Jung
    Lee, Ju-Hyun
    Chung, Jin-Haeng
    Kim, Miso
    Keam, Bhumsuk
    Kim, Tae Min
    Kim, Dong-Wan
    Heo, Dae Seog
    Lee, Jong Seok
    THORACIC CANCER, 2021, 12 (05) : 619 - 630
  • [7] Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3+anti-PD-1-based immunotherapies
    Gide, Tuba N.
    Paver, Elizabeth C.
    Yaseen, Zarwa
    Maher, Nigel
    Adegoke, Nurudeen
    Menzies, Alexander M.
    da Silva, Ines Pires
    Wilmott, James S.
    Long, Georgina V.
    Scolyer, Richard A.
    ONCOIMMUNOLOGY, 2023, 12 (01):
  • [8] Impact of Body Mass Index on Outcomes in an Asian population of Advanced Renal Cell Carcinoma and Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors
    Ishihara, Hiroki
    Ishiyama, Yudai
    Nemoto, Yuki
    Nakamura, Kazutaka
    Tachibana, Hidekazu
    Fukuda, Hironori
    Yoshida, Kazuhiko
    Kobayashi, Hirohito
    Iizuka, Junpei
    Shimmura, Hiroaki
    Hashimoto, Yasunobu
    Tanabe, Kazunari
    Kondo, Tsunenori
    Takagi, Toshio
    CLINICAL GENITOURINARY CANCER, 2022, 21 (01) : 136 - 145
  • [9] Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma
    Talukder, Rafee
    Bakaloudi, Dimitra Rafailia
    Makrakis, Dimitrios
    Diamantopoulos, Leonidas N.
    Enright, Thomas
    Leary, Jacob B.
    Raychaudhuri, Ruben
    Tripathi, Nishita
    Agarwal, Neeraj
    Jindal, Tanya
    Brown, Jason R.
    Zakharia, Yousef
    Rey-Cardenas, Macarena
    Castellano, Daniel
    Nguyen, Charles B.
    Alva, Ajjai
    Zakopoulou, Roubini
    Bamias, Aristotelis
    Barrera, Rafael Morales
    Marmolejo, David
    Drakaki, Alexandra
    Pinato, David J.
    Korolewicz, James
    Buznego, Lucia Alonso
    Duran, Ignacio
    Carballeira, Clara Castro
    Mckay, Rana R.
    Stewart, Tyler F.
    Gupta, Shilpa
    Barata, Pedro
    Yu, Evan Y.
    Koshkin, Vadim S.
    Khaki, Ali Raza
    Grivas, Petros
    CLINICAL GENITOURINARY CANCER, 2025, 23 (01)
  • [10] Immune Co-inhibitory Receptors CTLA-4, PD-1, TIGIT, LAG-3, and TIM-3 in Upper Tract Urothelial Carcinomas: A Large Cohort Study
    Jin, Shengming
    Shang, Zhi
    Wang, Wenwen
    Gu, Chengyuan
    Wei, Yu
    Zhu, Yu
    Yang, Chen
    Zhang, Tiantian
    Zhu, Yao
    Zhu, Yiping
    Wu, Junlong
    Ye, Dingwei
    JOURNAL OF IMMUNOTHERAPY, 2023, 46 (04) : 154 - 159